{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:03:31Z","timestamp":1788973411994,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10620-023-08091-0","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T15:02:05Z","timestamp":1693839725000},"page":"4221-4229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First Clostridioides difficile Recurrence Is Highest Following Concomitant Antimicrobial Administration During and Within 30 Days of Treatment"],"prefix":"10.1007","volume":"68","author":[{"given":"Abdelkader","family":"Chaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Damianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssam","family":"Al-Nahhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sohail","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7643-9576","authenticated-orcid":false,"given":"Paul","family":"Feuerstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"8091_CR1","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","volume":"379","author":"SS Magill","year":"2018","unstructured":"Magill SS, O\u2019Leary E, Janelle SJ et al. Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. N Engl J Med 2018;379:1732\u20131744.","journal-title":"N Engl J Med"},{"key":"8091_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med 2020;382:1320\u20131330.","journal-title":"N Engl J Med"},{"key":"8091_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1\u2013e48.","journal-title":"Clin Infect Dis"},{"key":"8091_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422\u2013431.","journal-title":"N Engl J Med"},{"key":"8091_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281\u2013289.","journal-title":"Lancet Infect Dis"},{"key":"8091_CR6","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","volume":"97","author":"LV McFarland","year":"2002","unstructured":"McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769\u20131775.","journal-title":"Am J Gastroenterol"},{"key":"8091_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1086\/430315","volume":"40","author":"J Pepin","year":"2005","unstructured":"Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591\u20131597.","journal-title":"Clin Infect Dis"},{"key":"8091_CR8","doi-asserted-by":"publisher","first-page":"1081 e1\u20137","DOI":"10.1016\/j.amjmed.2011.05.032","volume":"124","author":"DM Drekonja","year":"2011","unstructured":"Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med 2011;124:1081 e1\u20137.","journal-title":"Am J Med"},{"key":"8091_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archinternmed.2010.73","volume":"170","author":"A Linsky","year":"2010","unstructured":"Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772\u2013778.","journal-title":"Arch Intern Med"},{"key":"8091_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1017\/S0950268818000390","volume":"146","author":"SJ Jin","year":"2018","unstructured":"Jin SJ, Seo KH, Wi YM. The effect of concomitant use of systemic antibiotics in patients with Clostridium difficile infection receiving metronidazole therapy. Epidemiol Infect 2018;146:558\u2013564.","journal-title":"Epidemiol Infect"},{"key":"8091_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/MCG.0b013e3182431d78","volume":"46","author":"YG Kim","year":"2012","unstructured":"Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012;46:397\u2013400.","journal-title":"J Clin Gastroenterol"},{"key":"8091_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(00)03592-3","volume":"357","author":"L Kyne","year":"2001","unstructured":"Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189\u2013193.","journal-title":"Lancet"},{"key":"8091_CR13","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/ajg.2013.333","volume":"108","author":"DE Freedberg","year":"2013","unstructured":"Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:1794\u20131801.","journal-title":"Am J Gastroenterol"},{"key":"8091_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","volume":"27","author":"J van Prehn","year":"2021","unstructured":"van Prehn J, Reigadas E, Vogelzang EH et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021;27:S1\u2013S21.","journal-title":"Clin Microbiol Infect"},{"key":"8091_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.7326\/M20-7355","volume":"174","author":"RA Lee","year":"2021","unstructured":"Lee RA, Centor RM, Humphrey LL et al. Appropriate se of short-course antibiotics in common infections: best practice advice from the American college of physicians. Ann Intern Med 2021;174:822\u2013827.","journal-title":"Ann Intern Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08091-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:09:20Z","timestamp":1697108960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8091"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08091-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PF receives research support from Rebiotix\/Ferring, Vedanta, Finch, Pfizer and Adare Pharmaceuticals. PF is on the speakers bureau for Ferring, SERES and Takeda. PF serves as a consultant for Ferring\/Rebiotix, SERES, Takeda and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Yale University School of Medicine Human Investigation Committee (i.e., institutional review board) approved the study with a waiver to obtain consent from the study subjects given the retrospective study design (HIC No. 1510016606).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}